Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.
Diamant ThaҫiRonald B VenderMenno A de RieCurdin ConradDavid M PariserBruce E StroberVeerle VanvoordenMaggie WangCynthia MaddenDirk de CuyperAlexa B KimballPublished in: The British journal of dermatology (2023)
Clinical responses observed through week 16 of BE SURE in patients randomized to bimekizumab were sustained through 104 weeks of treatment, regardless of Q4W or Q8W maintenance dosing. Response rates were also sustained through week 104 in patients who switched from adalimumab to bimekizumab at week 24, and were similar to those observed in the bimekizumab groups. Bimekizumab was well tolerated with no new safety signals.
Keyphrases
- open label
- phase iii
- placebo controlled
- study protocol
- randomized controlled trial
- phase ii
- clinical trial
- double blind
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- rheumatoid arthritis
- gestational age
- phase ii study
- prognostic factors
- squamous cell carcinoma
- early onset
- high intensity
- systematic review
- patient reported